Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Completed
Bial - Portela C S.A.
Phase 3
2011-03-01
Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an
estimated incidence of 4.5-16/100,000 persons/year.
BIA 9-1067 is currently being developed by BIAL (Portela & Cª,S.A.) to be used in addition to
L-DOPA (Levodopa) /carbidopa or L-DOPA (Levodopa) / preparations in PD patients. Promising
results have been obtained for BIA 9-1067 in previous studies.
Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial
Completed
Rabin Medical Center
Phase 3
2013-05-01
The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by
subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for
additional three years.
Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment
Completed
Bial - Portela C S.A.
Phase 1
2010-03-01
The purpose of this study is to assess the pharmacokinetics (PK) of BIA 9-1067 in patients
with moderate chronic hepatic impairment and in matched healthy subjects.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
